Stahl Eye Center, Inc. (www.StahlEyeCenter.com)
Participants in the study will be treated with the medication twice a day for a month, including right after surgery, to permanently improve visual acuity. Restasis is more commonly indicated to treat Dry Eye Syndrome by increasing the eyes’ natural ability to produce tears.
Marc Werner, M.D., Partner at Stahl Eye Center, said, “This study will analyze the effect of restasis on patient comfort, healing time and clarity of vision during rehabilitation after LASIK surgery. Stahl remains in the forefront of laser vision correction, and we hope this innovation will make our use of bladeless LASIK even more effective.”
Dr. Werner and his colleagues estimate the study will include hundreds of participants who will each be treated with restasis and analyzed on a regular basis using a series of metrics. Restasis was originally developed to treat Dry Eye Syndrome because prior treatments using over-the-counter tear drops provided only temporary relief.
Participants in the study will first undergo Stahl’s bladeless LASIK through the
Intralase® method. Intralase uses tiny bursts of laser light for increased safety compared to the mechanical metal blade otherwise employed during the first step of the LASIK procedure. Other benefits include a decrease in corneal scarring, increased surgical accuracy and improved low-light vision compared to standard LASIK.
For more information, please call 888-557-4448;
